Analyst firms · Raymond James · KRRO

Raymond James KRRO price target and rating history

Korro Bio Inc. (KRRO) · Health Care

Raymond James rates Korro Bio Inc. (KRRO) Outperform with a $23 price target, as of its latest action on Mar 13, 2026. It has published 3 rating actions on KRRO since October 2024, including 1 upgrade and 1 downgrade. Across 7 firms with a KRRO price target in the last 12 months, the median target is $21. Raymond James's $23 is 10% above that.

Current rating
Outperform
Price target
$23
Median target, all firms
$21
Actions on KRRO
3

Raymond James price target on KRRO

$153$88$2320252026
Raymond James price target on KRRO, each point a stated target, October 2024 to March 2026.

Every Raymond James rating on KRRO

How other firms rate KRRO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
CitigroupBuy$21May 18, 2026
Raymond JamesOutperform$23Mar 13, 2026
William BlairOutperformFeb 17, 2026
Piper SandlerOverweight$30Jan 29, 2026
Chardan Capital MarketsBuy$15Jan 29, 2026
H.C. WainwrightBuy$20Jan 29, 2026
Cantor FitzgeraldOverweight$21Jan 28, 2026
OppenheimerOutperform$22Jan 28, 2026

Questions about Raymond James and KRRO

What is Raymond James's price target for KRRO?
Raymond James's latest stated price target for Korro Bio Inc. (KRRO) is $23, from its action on Mar 13, 2026.
What is Raymond James's rating on KRRO?
Raymond James rates KRRO Outperform, a bullish rating, as of Mar 13, 2026.
When did Raymond James last change its view on KRRO?
On Mar 13, 2026, Raymond James upgrades to Outperform from Mkt Perform, price target $23.
How does Raymond James's KRRO target compare with other analysts?
Across 7 firms with a KRRO price target in the last 12 months, the median target is $21. Raymond James's $23 is 10% above that.

More KRRO rating histories

All Raymond James ratingsKRRO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.